Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Scientists identify microRNAs that appear to play a role in the development of platelets

Scientists have identified a handful of microRNAs (miRNAs) that appear to play a significant role in the development of platelets - blood cells critical to the body's ability to form clots following an injury.

21 Mar 2006

Study to Rituximab's potential to preserve insulin production in newly diagnosed type 1 diabetics

A drug used to treat lymphoma, rheumatoid arthritis and other immune disorders may enable newly-diagnosed type 1 diabetics to save some of their pancreas function and thereby reduce their susceptibility to long-term complications.

20 Mar 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

Schering-Plough provides update on phase II study of Vicriviroc

Schering-Plough Corporation has provided an update on vicriviroc, its investigational CCR5 receptor antagonist, currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing Phase II clinical study of 118 U.S. treatment-experienced HIV patients.

6 Mar 2006

Link between rheumatoid arthritis and cancer examined

Rheumatoid arthritis is an inflammatory disease of the immune system and is thought to be linked to an increased risk of cancers of the lymphatic system.

28 Feb 2006

Combination therapy improves Acquired Immunodeficiency Syndrome-Related Lymphoma outcome

Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.

27 Feb 2006

Study associates chronic, severe inflammation with increased lymphoma risk among RA patients

An inflammatory disease of the immune system, rheumatoid arthritis (RA) is associated with increased occurrence of lymphoma--or cancers of the lymphatic system, which plays an integral role in the body's ability to fight infection.

27 Feb 2006

Oddly shaped DNA can cause DNA breaks in mammalian cells

When otherwise normal DNA adopts an unusual shape called Z-DNA, it can lead to the kind of genetic instability associated with cancers such as leukemia and lymphoma, according to a study by researchers at The University of Texas M. D. Anderson Cancer Center.

21 Feb 2006

Protein levels predict bone marrow transplant survival

Researchers say that protein levels can predict which bone marrow transplant patients are likely develop a deadly complication a week after the procedure and well before any symptoms occur.

19 Feb 2006

Protein level predicts who will develop graft vs. host disease after marrow transplant

Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

17 Feb 2006

Rituximab maintenance therapy dramatically improves survival for patients with lymphoma

Two years of maintenance therapy with rituximab dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkin's Lymphoma (NHL).

14 Feb 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

FDA affirms safety of Aspartame

The Calorie Control Council has stated that a rat study conducted by Italy's Ramazzini Institute is totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA) has said they are not recommending any changes in the use of aspartame.

13 Feb 2006

CT enteroclysis should replace conventional enteroclysis in patients with Crohn's disease

The diagnostic value of CT enteroclysis is superior to conventional enteroclysis, previously considered the gold standard, as an imaging method for the evaluation of the small bowel in patients with Crohn's disease, a new study shows.

7 Feb 2006

PET imaging has the potential to improve cancer care management

A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment

7 Feb 2006

Education campaign on umbilical cord and placental blood donation

The New Jersey Department of Health and Senior Services Commissioner Fred M. Jacobs, M.D., J.D. has launched an educational campaign to inform expectant mothers of the life-saving value of newborn umbilical cord and placental blood.

23 Jan 2006

Black box warnings for two eczema creams

Food and Drug Administration officials in the U.S. have announced that two prescription creams to treat eczema will now carry strong warnings about the possible risk of skin cancer, lymphoma and other cancers.

22 Jan 2006

TCF21 gene shown to be a tumor suppressor

Researchers have identified a new and unusual tumor suppressor gene that may be important in cancers of the lung and head and neck. The study shows that restoring the inactivated gene can slow the growth of tumor cells.

18 Jan 2006

Hopes dashed for peanut allergy drug Xolair

Hopes have been dashed for a potential treatment for peanut allergies following the severe reactions suffered by two children during a clinical trial.

18 Jan 2006

St. Jude projects 90 percent cure rate for acute lymphoblastic leukemia

The cure rate for the once almost universally fatal childhood cancer acute lymphoblastic leukemia (ALL) could reach 90 percent in the near future, thanks to improvements in diagnosis and treatment over the past four decades, according to investigators at St. Jude Children's Research Hospital.

11 Jan 2006